Clinical application of QuantiFERON-TB Gold in-tube in the diagnosis and treatment of tuberculosis

  • Guangming Chen
  • Huabin WangEmail author
  • Yanhong Wang


At present, although it has made great progress in the diagnosis and treatment of tuberculosis, tuberculosis is still an important cause of morbidity and mortality. There were approximately 8.6 million new cases of tuberculosis in 2012, and approximately 1.3 million people died from tuberculosis. Early diagnosis and timely treatment are essential for controlling the spread of tuberculosis infection and reducing mortality. Conventional methods of Mycobacterium tuberculosis detection such as acid-fast staining microscopy and tuberculin skin test are widely used, but with low sensitivity or specificity. In recent years, a newly developed quantitative test, γ-interferon release test (IGRA), has been recognized and widely applied to the early diagnosis and monitoring of tuberculosis. QuantiFERON-TB Gold in-tube (QFT-GIT) is one of the mature IGRA methods. This paper summarizes the researches on QFT-GIT in recent years and introduces its principles, methodology, clinical application, and factors of uncertain results for the diagnosis and treatment of tuberculosis.


Mycobacterium tuberculosis infection QuantiFERON-TB Gold in-tube Clinical application False negative Uncertain results 



This research received the grant from Science Technology Department of Zhejiang province, China (2017C33206).

Compliance with ethical standards

Conflict of interest

The authors declared that they have no conflicts of interest.


  1. 1.
    World Health Organization (2016) Global tuberculosis report 2016[R]. WHO, Geneva, pp 15–42Google Scholar
  2. 2.
    Kim YJ, Kang JY, Sl K et al (2018) Predictors for false-negative QuantiFERON-TB Gold assay results in patients with extrapulmonary tuberculosis[J]. BMC Infect Dis 18(1):457CrossRefGoogle Scholar
  3. 3.
    Cruz AT, Geltemeyer AM, Starke JR et al (2011) Comparing the tuberculin skin test and T-SPOT.TB blood test in children[J]. Pediatrics 127(1):e31–e38CrossRefGoogle Scholar
  4. 4.
    Burl S, Adetifa UJ, Cox M et al (2010) The tuberculin skin test (TST) is affected by recent BCG vaccination but not by exposure to non-tuberculosis mycobacteria (NTM) during early life[J]. PloS one 5(8):e12287CrossRefGoogle Scholar
  5. 5.
    Sohn H, Aero AD, Menzies D et al (2014) Xpert MTB/RIF testing in a low tuberculosis incidence, high-resource setting: limitations in accuracy and clinical impact[J]. Clin Infect Dis 58(7):970–976CrossRefGoogle Scholar
  6. 6.
    Bunsow E, Ruiz-Serrano MJ, Lopez Roa P et al (2014) Evaluation of GeneXpert MTB/RIF for the detection of Mycobacterium tuberculosis and resistance to rifampin in clinical specimens[J]. J Infect 68(4):338–343CrossRefGoogle Scholar
  7. 7.
    Wang JY, Zhou DZ, Xu YL (2016) Clinical application of release enzyme immunoassay in vitro for mycobacterium tuberculosis[J]. Modem Pract Med 28(1):32–33. CrossRefGoogle Scholar
  8. 8.
    Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update[J]. Ann Intern Med 149(3):177–184CrossRefGoogle Scholar
  9. 9.
    Kobashi Y, Mouri K, Yagi S et al (2008) Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis[J]. Chest 133(5):1196–1202CrossRefGoogle Scholar
  10. 10.
    Sester M, Sotgiu G, Lange C et al (2011) Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis[J]. Eur Respir J 37(1):100–111CrossRefGoogle Scholar
  11. 11.
    Lei B, Tao L, Ni D et al (2015) Fluctuating behavior and influential factors in the performance of the QuantiFERON-TB Gold in-tube assay in the diagnosis of tuberculosis[J]. PLoS One 10(8):e0103763CrossRefGoogle Scholar
  12. 12.
    Du F, Xie L, Zhang Y et al (2018) Prospective comparison of QFT-GIT and T-SPOT.TB assays for diagnosis of active tuberculosis[J]. Sci Rep 8(1):5882CrossRefGoogle Scholar
  13. 13.
    Abubakar I, Lalvan A, Southern J et al (2018) Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study[J]. Health Technol Assess 22(56):1–96CrossRefGoogle Scholar
  14. 14.
    Nijhawan AE, Iroh PA, Brown LS et al (2016) Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold in-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA[J]. BMC Infect Dis 16(1):564CrossRefGoogle Scholar
  15. 15.
    Jeon Y, Kim MJ, Lee WI (2017) Diagnostic utility of new equation for active tuberculosis based on parameters of interferon-γ release assay[J]. Lab Med 48(3):214–219CrossRefGoogle Scholar
  16. 16.
    Ayubi E, Doosti-Irani A, Sanjari MA et al (2016) The clinical usefulness of tuberculin skin test versus interferon-gamma release assays for diagnosis of latent tuberculosis in HIV patients: A Meta-Analysis[J]. PLoS One 11(9):e0161983CrossRefGoogle Scholar
  17. 17.
    Esmail H, Thienemann F, Oni T et al (2016) QuantiFERON conversion following tuberculin administration is common in HIV infection and relates to baseline response[J]. BMC Infect Dis 16(1):545CrossRefGoogle Scholar
  18. 18.
    Prabhavathi M, Ahamed Kabeer BS, Deenadayalan A et al (2016) In vitro QuantiFERON-TB gold antigen specific interleukin-1beta to diagnose TB among HIV-positive subjects[J]. Tuberculosis (Edinb) 96:27–30CrossRefGoogle Scholar
  19. 19.
    Danel C, Kabran M, Inwoley A et al (2014) Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa[J]. PLoS One 9(10):e107245CrossRefGoogle Scholar
  20. 20.
    Chang PC, Wang PH, Chen KT (2017) Use of the QuantiFERON-TB Gold in-tube test in the diagnosis and monitoring of treatment efficacy in active pulmonary tuberculosis[J]. Int J Environ Res Public Health:14(3)CrossRefGoogle Scholar
  21. 21.
    Katiyar SK, Sampath A, Bihari S et al (2008) Use of the QuantiFERON-TB Gold in-tube test to monitor treatment efficacy in active pulmonary tuberculosis[J]. Int J Tuberc Lung Dis 12(10):1146–1152PubMedGoogle Scholar
  22. 22.
    Johnson JL, Geldenhuys H, Thiel BA et al (2014) Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB Gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence Area[J]. Chest 145(3):612–617CrossRefGoogle Scholar
  23. 23.
    Seto J, Ahiko T (2014) Effectiveness of interferon-gamma release assays in the tuberculosis contact investigation of elderly people[J]. Kekkaku 89(4):503–508PubMedGoogle Scholar
  24. 24.
    Chen ZH, Yu YY, Dai SB, Zhang XP, Wan XJ, Tan YH (2014) Analysis of uncertain results of whole blood gamma-interferon release test QFT-GIT[J]. Chin J Clin Lab Sci 32(11):873–875. CrossRefGoogle Scholar
  25. 25.
    Mo WP, Zhong YC, Chen ZL, Zhang YY (2019) Analysis of causes of uncertainty in QFT results of gamma-interferon release test[J]. Clin Lab J (Electron Ed) 8(1):12–13Google Scholar
  26. 26.
    Telisinghe L, Amofa-Sekyi M, Maluzi K et al (2017) The sensitivity of the QuantiFERON®-TB Gold Plus assay in Zambian adults with active tuberculosis[J]. Int J Tuberc Lung Dis 21(6):690–696CrossRefGoogle Scholar
  27. 27.
    Kim CH, Lim JK, Yoo SS et al (2014) Diagnostic performance of the QuantiFERON-TB Gold in-tube assay and factors associated with nonpositive results in patients with miliary tuberculosis[J]. Clin Infect Dis 58(7):986–989CrossRefGoogle Scholar
  28. 28.
    Aichelburg MC, Mandorfer M, Tittes J et al (2014) The association of smoking with IGRA and TST results in HIV-1-infected subjects[J]. Int J Tuberc Lung Dis 18(6):709–716CrossRefGoogle Scholar
  29. 29.
    Choi JC, Jarlsberg LG, Grinsdale JA et al (2015) Reduced sensitivity of the QuantiFERON(®) test in diabetic patients with smear-negative tuberculosis[J]. Int J Tuberc Lung Dis 19(5):582–588CrossRefGoogle Scholar
  30. 30.
    Wang H, Zhen SP, Gao T (2018) Application of tuberculosis interferon gamma release assay (TB-IGRA) in the diagnosis of tuberculosis[J]. Clin Res Pract 3(25):97–98. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of General PracticeJinhua Municipal Central HospitalJinhuaPeople’s Republic of China
  2. 2.Central LaboratoryJinhua Municipal Central HospitalJinhuaPeople’s Republic of China
  3. 3.Department of Laboratory MedicineWenzhou Medical UniversityWenzhouPeople’s Republic of China

Personalised recommendations